Boston Scientific is to present data spanning its interventional cardiology, rhythm management and structural heart portfolios at the American College of Cardiology’s 65th Annual Scientific Session which will be held in Chicago, USA, April 2-4.
Scheduled abstracts will highlight ’real-world’ and clinical trial experiences with technologies developed to treat patients with a range of cardiovascular diseases. Topics to be presented include:
- One-year post US Food and Drug Administration (FDA) approval experience using the Watchman left atrial appendage closure (LAAC) device to reduce the risk of stroke in people with non-valvular atrial fibrillation who cannot take warfarin.
- Two-year safety and efficacy outcomes with the Synergy bioabsorbable polymer drug-eluting stent system in patients with coronary artery disease from the EVOLVE II trial.
- Performance and clinical outcomes of the Lotus transcatheter aortic valve replacement (TAVR) system in patients with severe calcific aortic stenosis from the RESPOND trial.
- First-ever preclinical data evaluating the Boston Scientific modular therapy approach and communications compatibility between its leadless pacemaker and the Emblem subcutaneous implantable defibrillator (S-ICD).
- Primary results of the NAVIGATE X4 study, a multicentre clinical trial that, according to a company release, led to the US Food and Drug Administration (FDA) approval of Acuity X4 Quadripolar left ventricular (LV) leads in February 2016.
Keith Dawkins, global chief medical officer, Boston Scientific, says, “We are also looking forward to unveiling the first data from our leadless pacemaker program.”
